Quoin Pharmaceuticals Ltd. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price
Quoin Pharmaceuticals Ltd. (QNRX) had Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price of $7.37 per share as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice · last filed 2026-08-14
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $7.37.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $7.38.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $9.99.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price $9.07.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $7.37 10-Q · filed 2026-08-14 | |
| 2026-03-31 | $7.38 10-Q · filed 2026-05-07 | |
| 2025-12-31 | $9.99 10-K · filed 2026-03-26 | |
| 2025-09-30 | $9.07 10-Q · filed 2025-11-06 | |
| 2025-06-30 | $9.07 10-Q · filed 2025-08-07 | |
| 2024-12-31 | $27.30 10-K · filed 2026-03-26 | $0.78 10-K · filed 2025-03-13 |
| 2023-12-31 | $6.62 10-K · filed 2025-03-13 | |
| 2022-12-31 | $210.00 10-K · filed 2024-03-14 | $17.50 10-K · filed 2023-03-15 |
| 2022-09-30 | $17.50 6-K · filed 2022-11-10 | |
| 2022-06-30 | $17.50 6-K · filed 2022-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 |